Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNR-085
- Development stage
- Unknown
- Lead developer
- AO GENERIUM
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GNR-085 is a humanized monoclonal antibody biosimilar candidate of ocrelizumab, developed by AO GENERIUM for the treatment of multiple sclerosis (MS). It selectively targets the CD20 antigen, a protein expressed on the surface of pre-B and mature B lymphocytes but not on stem cells or plasma cells. By binding to CD20, GNR-085 mediates the depletion of CD20-positive B cells through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This depletion modulates the autoimmune activity and inflammatory response associated with MS pathogenesis. The drug is currently in Phase 1 clinical development as a biosimilar alternative to established anti-CD20 therapies.
- Other names
- ocrelizumab biosimilar
02
Targets
Beyond the preview
Go deeper on GNR-085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNR-085.